retatrutide glp1 vs. Tirzepatide: The Next-Gen GLP-1 Showdown Retatrutide for weight loss: Study

doi: 10.1016/j.bbrc.2009.01.003

In 2019, the Mueller group showed that GLP1 activation directly inhibits AMPK activation

As both the liver and skeletal muscle store most of the glycogen in humans, current research supporting increased glucose uptake and glycogen synthesis within these tissues provides plausibility in explaining the phenomenon where individuals prescribed GLP-1 agonists can consume greater amounts of carbohydrates while still losing weight

Compounded Tirzepatide targets both GIP and GLP-1 receptors a dual-action mechanism that produces a more pronounced metabolic response for many patients

Preclinical research suggests GLP-1 receptor agonists may influence this reward response, potentially affecting the reinforcing properties of addictive substances, though human evidence remains limited